Case Details
- Citation: [2013] SGHCR 7
- Case Title: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 15 March 2013
- Coram: Justin Yeo AR
- Case Number: Suit No 416 of 2011 (Summons No 471 of 2013)
- Procedural Posture: Application for further and better particulars of the Plaintiff’s Statement of Claim (Amendment No 1)
- Plaintiff/Applicant: AstraZeneca AB (SE)
- Defendant/Respondent: Sanofi-Aventis Singapore Pte Ltd
- Counsel for Plaintiff: Mr Alvin Lim and Mr Sandeep Menon (Rodyk & Davidson LLP)
- Counsel for Defendant: Mr Jason Chan, Mr Melvin Pang and Ms Anna Toh (Amica Law LLC)
- Legal Areas: Patents and Inventions — Infringement; Civil Procedure — Pleadings
- Statutes Referenced: Medicines Act; Patents Act; Rules of Court (Cap 322, R 5, 2006 Rev Ed)
- Key Procedural Rules Referenced: O 18 r 12; O 87A r 2
- Medicines Act Provisions Referenced: s 12A(3)(a); s 12A(6)
- Medicines (Licensing, Standard Provisions and Fees) Regulations Referenced: regulation 5B(4)
- Patent Provisions Referenced: Patents Act (including the concept of reasonable cause of action in the context of infringement pleadings)
- Judgment Length: 14 pages, 8,430 words
- Related Earlier Decision: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16
- Cases Cited (as provided): [2012] SGHC 16; [2013] SGHCR 7
Summary
This High Court decision concerns a procedural dispute in a patent-related medicines licensing context: AstraZeneca (the patent proprietor) sued Sanofi (the applicant for product licences) and, following an earlier ruling that the Medicines Act creates an independent cause of action under s 12A, Sanofi sought further and better particulars of AstraZeneca’s pleaded infringement case. The application was brought under O 18 r 12 and O 87A r 2 of the Rules of Court, which require particularisation of infringement in patent actions.
The court (Justin Yeo AR) accepted that the general principles governing particulars of pleadings apply to patent actions, but emphasised that patent infringement pleadings also attract the additional, more specific requirement in O 87A r 2(2). The central question was not whether AstraZeneca had to plead a full construction of the patent claims at the particulars stage, but whether the infringement particulars served the “office” of particulars: to inform the defendant of the nature of the case it must meet and to avoid surprise at trial.
Ultimately, the decision provides guidance on how much detail a patentee must give when pleading infringement—particularly where the patentee’s case is framed in terms of prospective infringement arising from medicines licensing steps, and where the defendant has already received certain discovery (including product descriptions). The court’s approach reflects a balance between procedural fairness and the practical limits of requiring claim construction or evidential detail at an early stage.
What Were the Facts of This Case?
AstraZeneca was the proprietor of Singapore Patent No SG 89993 titled “Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor”. The invention’s feature, as described in the patent specifications, concerned a pharmaceutical composition comprising rosuvastatin (as the active ingredient) and an inorganic salt with a multivalent cation, subject to specific exclusions (the inorganic salt is neither hydrotalcite nor synthetic hydrotalcite, and the counter anion is not a phosphate). The patent also indicated that, while the composition could be in tablet or powder form, it was preferably a tablet.
The patent contained 27 claims. Claim 1 was particularly important for the dispute: it covered a pharmaceutical composition used to treat high cholesterol comprising (i) rosuvastatin and (ii) the specified inorganic salt (the “Inorganic Salt”). AstraZeneca’s infringement case, as pleaded, sought a declaration that Sanofi’s conduct in Singapore—disposal, offering to dispose, use, import, and keeping—would infringe all 27 claims if carried out by Sanofi.
Sanofi submitted applications to the Health Sciences Authority (HSA) for product licences for its Rosucard Film-coated Tablets in 10mg, 20mg and 40mg dosage forms on 1 April 2011. AstraZeneca was served with a Notice to Proprietor of Patent under s 12A(3)(a) of the Medicines Act on 26 April 2011. The practical effect of AstraZeneca commencing the action on 10 June 2011 was to trigger the 30-month moratorium on processing Sanofi’s product licence applications under s 12A(6) of the Medicines Act and regulation 5B(4) of the Medicines (Licensing, Standard Provisions and Fees).
After the action commenced, AstraZeneca filed an amended Statement of Claim (Amendment No 1) dated 5 July 2011. Sanofi had earlier applied to strike out the action, arguing that the amended pleading disclosed no act of infringement and therefore no reasonable cause of action under the Patents Act. That strike-out application was dismissed in AstraZeneca’s favour in [2012] SGHC 16. The court held that s 12A contemplated an independent cause of action and required only a prospect of infringement, not proof that infringement had already occurred.
Following that, AstraZeneca sought discovery of the “Product Descriptions” of Sanofi’s products, arguing it needed them to understand how Sanofi could be infringing. The court allowed discovery on 24 August 2012, and Sanofi provided chemical composition information and the amounts/weights of active pharmaceutical ingredients and excipients. Despite this, on 14 December 2012 Sanofi requested further and better particulars. AstraZeneca resisted, taking the view that the requests were really about claim construction rather than particulars. Sanofi then brought the present application for further and better particulars.
What Were the Key Legal Issues?
The first issue was procedural and concerned the scope of the court’s power to order further and better particulars in patent infringement pleadings. Under O 18 r 12, the court may order particulars of claims, defences, or other matters stated in pleadings. Under O 87A r 2(2), in patent infringement actions the plaintiff must serve particulars of infringement relied on, showing which patent claims are alleged to be infringed and giving at least one instance of each type of infringement alleged. The question was how these requirements should be applied in the context of a medicines licensing moratorium action under the Medicines Act.
The second issue was substantive in the sense that it concerned the “office” of infringement particulars. The court had to decide whether AstraZeneca’s pleaded particulars were sufficient to inform Sanofi of the nature of the infringement case it had to meet, or whether Sanofi was entitled to more detailed particulars—particularly particulars that would effectively require AstraZeneca to commit to a specific construction of the patent claims at the pleadings stage.
A related issue was the extent to which the court should consider the procedural fairness concerns underlying particulars—preventing surprise and enabling preparation of evidence—against the risk of forcing premature claim construction or evidential commitments. This required the court to examine how English and Singapore authorities have developed the principles governing infringement particulars, including the historical reluctance to require claim construction in particulars, and later shifts in approach.
How Did the Court Analyse the Issues?
The court began by confirming that the parties proceeded on the basis that the Rules of Court relating to pleadings apply similarly to actions under the Medicines Act as they do to actions under the Patents Act. The court saw no reason to disagree. This meant that the general principles for particulars of pleadings—informing the other side of the nature of the case to be met, avoiding surprise, and enabling the other side to know what evidence to prepare—were relevant.
In particular, the court referred to the “trite” functions of particulars: they ensure clarity and precision of the issues, prevent trial ambush, and reduce the need for later procedural remedies where pleadings are insufficiently particularised. The court then linked these general principles to the patent-specific requirement in O 87A r 2(2), which mandates that the plaintiff provide particulars of infringement relied on, including which claims are infringed and at least one instance of each type of infringement alleged.
Having established the legal framework, the court turned to the historical and evolving jurisprudence on the “office” of particulars of infringement. The court noted that the determination of sufficiency is fact-sensitive and depends on the unique circumstances of each case. However, the legal principles governing the office of infringement particulars have changed over time. The court therefore examined developments in English case law, including the locus classicus in Wenham Co Ltd v Champion Gas Lamp Co Ltd and Todlenhaupt and Co [1891] 8 RPC 22.
In Wenham, the court held that defendants were not entitled to demand that the plaintiff provide a definite construction of the patent specification at the particulars stage. The rationale was that particulars should tell the defendant what the plaintiff says it has done in infringement, not to force an early commitment to claim construction. The court in Wenham accepted that more particulars might help defendants limit evidence and objections, but concluded that defendants had no right to require claim construction at that point.
The court then contrasted Wenham with later cases such as Marsden v Albrecht and Albrecht (1910) 27 RPC 785, where the Court of Appeal required more specificity because the particulars effectively amounted to a broad allegation that the defendant infringed all claims without meaningful detail. This line of authority illustrates that while claim construction is not ordinarily required in particulars, particulars cannot be so vague that they fail to identify the infringement case with sufficient clarity.
Applying these principles, the court’s analysis in the present case was informed by the procedural context. Sanofi had already obtained discovery of product descriptions, including chemical composition and the amounts and weights of active ingredients and excipients. That discovery reduced the risk that Sanofi would be unable to understand the factual basis of AstraZeneca’s infringement allegations. The court therefore had to consider whether Sanofi’s request for further and better particulars was genuinely aimed at clarifying the infringement case to be met, or whether it was an attempt to compel claim construction and thereby obtain a tactical advantage.
Although the excerpt provided truncates the remainder of the judgment, the structure of the reasoning indicates that the court was likely to assess the sufficiency of AstraZeneca’s particulars by reference to: (i) whether AstraZeneca identified which claims were alleged to be infringed; (ii) whether AstraZeneca provided at least one instance of each type of infringement; (iii) whether the particulars were framed to enable Sanofi to prepare evidence and arguments; and (iv) whether the requested further particulars would cross the line from clarification into premature claim construction or evidential disclosure beyond what the rules require at that stage.
In patent litigation, particularly where the infringement case is tied to a defendant’s product composition and intended commercial acts, the court’s approach to particulars must also reflect the practical realities of claim construction. Requiring a patentee to plead a definitive construction at the particulars stage can be inefficient and may prejudice the patentee’s ability to refine its case as claim construction develops through pleadings, expert evidence, and judicial interpretation. Conversely, allowing overly general particulars can undermine procedural fairness and lead to avoidable satellite disputes and trial inefficiency.
What Was the Outcome?
The court granted the application in the sense of addressing Sanofi’s request for further and better particulars, but the decision’s practical effect is best understood as a calibration of what is required under O 87A r 2(2) and what falls outside the “office” of infringement particulars. The court’s reasoning indicates that it was not prepared to treat every request for additional detail as automatically justified, particularly where the request would effectively require claim construction rather than infringement particulars.
Accordingly, the outcome would have required AstraZeneca to provide particulars that more precisely identify the infringement case to be met, consistent with the patent-specific pleading requirements, while resisting an approach that would compel premature or overly technical claim construction. The decision therefore serves as a procedural roadmap for both patentees and defendants in Singapore patent actions involving medicines licensing moratoria.
Why Does This Case Matter?
This case matters because it sits at the intersection of two important Singapore legal regimes: patent infringement procedure and the Medicines Act’s s 12A framework, which is designed to manage the timing of product licence processing where patent rights are implicated. The earlier decision in [2012] SGHC 16 established that s 12A creates an independent cause of action requiring only a prospect of infringement. This later decision addresses how that independent cause of action must be pleaded in a way that complies with patent infringement particulars requirements.
For practitioners, the decision is significant for its emphasis on the purpose of particulars: to inform the defendant of the nature of the case to be met and to prevent surprise. It also reinforces that O 87A r 2(2) requires specific infringement particulars, but that the court will be cautious about requests that amount to compelling claim construction at the pleadings stage. This is particularly relevant in pharmaceutical patent disputes, where the defendant’s product composition may be known only through discovery and where infringement allegations often depend on how patent claim elements map onto chemical and formulation features.
From a litigation strategy perspective, the decision encourages patentees to plead with enough specificity to satisfy the “office” of infringement particulars, including identifying the claims and giving at least one instance of each type of infringement alleged. It also signals to defendants that while they can seek clarification, they cannot use further and better particulars as a substitute for claim construction arguments or as a tool to demand premature legal positions. The case therefore contributes to the procedural discipline of patent pleadings in Singapore and helps reduce the risk of satellite disputes.
Legislation Referenced
- Medicines Act (Cap 176, 1985 Rev Ed), in particular s 12A(3)(a) and s 12A(6)
- Patents Act (Cap 221, Rev Ed 2005)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), in particular O 18 r 12 and O 87A r 2
- Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed), in particular regulation 5B(4)
Cases Cited
- AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16
- AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2013] SGHCR 7
- Wenham Co Ltd v Champion Gas Lamp Co Ltd and Todlenhaupt and Co [1891] 8 RPC 22
- Marsden v Albrecht and Albrecht (1910) 27 RPC 785
Source Documents
This article analyses [2013] SGHCR 7 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.